MRK stock news · Merck KGaA
Get alerts for MRK
Follow Merck KGaA (MRK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRKMilliporeSigma is celebrating 10 years of its SPARK™ program that encourages community service and STEM learning.
NeutralMerck KGaA marked 10 years of its employee volunteer program, which supports science education. The story reports no business change, so it does not alter the company's outlook.
Merck's stock went up after it reported better-than-expected earnings and strong sales for new products.
Good for MRKMerck beat estimates for adjusted earnings per share and sales, and its cancer-drug pipeline showed progress. Purchase timing helped sales, but the overall report supports Merck’s business prospects.
Bronstein, Gewirtz & Grossman, LLC is looking into Merck & Co., Inc. over some early trial results.
NeutralMerck's cancer-vaccine data showed a possible benefit, but a law firm is only investigating its early release. The story does not yet change Merck's outlook.
Moderna and Merck share results from their Phase 3 trial for the cancer vaccine Intismeran Autogene.
Good for MRKThe results show that a treatment combining intismeran autogene with KEYTRUDA reduced the risk of recurrence or death. The treatment is still investigational, so the story does not show whether it will lead to sales for Merck.
Merck KGaA will show 25 research papers at the ESMO 2026 conference.
NeutralMerck KGaA had 25 cancer-study abstracts accepted for ESMO 2026. The announcement names upcoming safety and survival data but gives no findings, so it does not change the outlook.
Big investors are making moves in 10 health care stocks today.
NeutralThe alert marked Merck's call trade bearish. It reports trading activity, not a company change, so it does not change Merck's outlook.
Structured Obligations Corp Select Notes Trust LT 2003-1 shared news about payments to its certificate holders.
NeutralThe trust report lists $0 in payments on Merck's bond for this period, but does not say a payment was due or missed. It gives no new information about the company's business.
Structured Obligations Corp says it will make payments to people holding Select Notes Trust LT 2003-2.
NeutralThe report lists $0 in payments on a Merck bond held by the trust for this period, but gives no reason or update on Merck's business, so it does not change the company's outlook.
Merck KGaA teams up with Nvidia, Microsoft, and Dawn Health to create AI support for patients.
NeutralMerck KGaA is working with 3 technology partners on AI support for people with rare tumors. The story reports no patient results or business gains, so it does not change the company's outlook.
The Energy sector dropped on Tuesday while safer areas like Health Care and Financials did well.
NeutralMerck shares rose 2.97% as Health Care led the sectors. The report gives no company news, so the session does not change its outlook.
Merck is stopping sales of its bacterial infection medicine Zinplava in Europe.
Bad for MRKMerck is ending Zinplava sales in Europe after stopping them in the United States. Losing another market for the drug is a business setback, though its sales are not reported.
Illinois Governor JB Pritzker criticized Trump and Darren Bailey for their healthcare ideas, saying they oppose life-saving vaccines.
NeutralMerck defended its combined vaccine amid debate over vaccine rules. The story reports no change to Merck’s business, so it does not shift the company’s outlook.
Merck & Co. says some directors and officers are leaving, while new ones are being chosen.
NeutralMerck named Paul J. Diaz to its board and two committees.
Cyclical industries did well in Tuesday's trading, while Health Care struggled behind.
NeutralMerck shares fell 1.13% as health care fell 1.07%. The report gives no new news about the company’s business, so its outlook is unchanged.
Stephen King criticizes Trump’s new press secretary for her old posts about vaccines and election claims.
NeutralThe story mentions Merck’s recent share decline but reports no new company development or link between the dispute and Merck’s business.
John Moolenaar is asking the Defense Department to put 120 Chinese schools and tech labs on a funding watchlist.
NeutralLawmakers asked Merck for information about clinical trials in China and raised data-protection and research-site concerns. They said there was no evidence of illegal activity or wrongdoing, and the story reports no action against Merck, so its outlook is unchanged.
Merck says its new skin treatment might work well.
Good for MRKMerck said its experimental skin drug beat placebo on the main week-16 measure. Side effects were reported more often, and the low dose did not improve quality-of-life scores, but the active-dose results support a positive read.
Alpha Buying: See where NVIDIA and Merck are putting their money.
Good for MRKMerck owns several small drug-platform companies and uses its scientists and regulatory teams to vet investments. That expertise increases the chance these holdings add value to Merck's business.
Merck says its new diabetes drug works just as well as Roche's treatment.
NeutralMerck's eye drug matched Roche's Lucentis in vision benefit, but higher eye-related adverse events make the trial result mixed, so it does not change the company's outlook.
Structured Obligations Corp Select Notes Trust LT 2003-1 shared news about payments to its certificate holders.
NeutralMerck is listed among underlying securities with no payment recorded this period, and the trustee disclaims verification, so the filing does not change Merck's picture.
Structured Obligations Corp Select Notes Trust LT 2003-2 shared news about payments to its investors.
Good for MRKMerck's note is shown paying $96,000 to the trust during the period, indicating the trust received interest from that Merck security.
Merck is one step closer to getting approval in Europe for its Keytruda treatment for bladder cancer.
Good for MRKMerck won an EU committee recommendation for KEYTRUDA plus Padcev, strengthening its bladder cancer franchise ahead of a European Commission decision expected in Q4 2026.
Congresswoman Maria Elvira Salazar buys stocks in Elon Musk's SpaceX and Warren Buffett's Berkshire Hathaway.
NeutralA congresswoman bought Merck shares the day Moderna announced a vaccine using Keytruda. The note is attention-grabbing but does not change Merck’s picture.
Rep. Maria Elvira Salazar spent more than $34K to buy stock in Merck & Co.
NeutralA congressmember filed purchases of Merck shares, while the stock fell about 2% the same day; these facts balance, so the report does not change Merck's outlook.
More than 1 in 5 seniors are reaching Medicare's $2,000 drug limit as spending approaches $346 billion.
Bad for MRKA court ruling lets Medicare negotiate prices for some costly drugs, increasing pricing pressure on Merck and signaling higher policy risk for its drug sales.